Orion anticipates strong turnover, the stock rose rapidly

Pharmaceutical manufacturer On Wednesday, Orion’s share was even up by more than 12 percent after the company gave its guidance for the current year and reported positive estimates of the sales of its prostate cancer drug sold under the trade name Nubeqa.

Orion announced on Wednesday morning that the annual Nubeqa turnover it records may exceed one billion euros in the future. In the afternoon, the company exceptionally specified with another announcement that the limit will be exceeded by the end of the current decade.

“The Nubeqa product has become Orion’s largest product by far, and its financial importance to the company will grow even more,” Orion said in its press release.

Orion’s estimates caused the company’s stock to rise sharply on the Helsinki Stock Exchange. On Wednesday, Orion’s more traded B share rose 12.0 percent to 70.30 euros. At its highest, the share traded at 70.60 euros.

Orion has developed the cancer drug Nubeqa together with the German Bayer. Orion is responsible for manufacturing the medicine. Bayer has the rights to commercialize the drug worldwide.

Orion’s Nubeqa turnover consists of both medicinal tablet sales to Bayer and royalties from Bayer.

A medicine’s sales potential is affected by various changing conditions, such as the regulatory environment, the market environment and the product’s indications for use, Orion says.

Orion anticipates that its Nubeqa turnover will continue its strong growth in the current year. In its press release, Orion indicates that its turnover will increase to 1.9–2.1 billion euros this year thanks to Nubeqa. The company estimates that its operating result will rise to 550–750 million euros.

Equity research company Inderes describes Orion’s guidance for the current year as “strong”.

“Overall, the announcement is a positive surprise. The guidance for 2026 indicates that Nubeqa’s sales growth will accelerate faster than our previous expectations,” writes the analyst Antti Siltanen in his comment in Inderes’ morning review.

Orion publishes last year’s results in February. In 2024, Orion’s turnover was 1.5 billion euros and the operating result was 417 million euros.